Drug for use in combination, and use thereof for preparing drugs for treatment of high-grade brain tumors in response to ineffective standard treatment for postoperative recurrence

Abstract

A drug for use in combination for treating high-grade brain tumors in response to ineffective standard treatment for postoperative recurrence. The drug for includes chlorogenic acid and temozolomide of the same or different unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. A pharmaceutical composition includes chlorogenic acid and temozolomide can be used to prepare a drug for treatment of high-grade brain tumors for which standard treatment for postoperative recurrence is ineffective.

1 . A drug combination for treatment of high-grade brain tumors that recur after surgery and do not response to standard treatment, characterized in that said combination contains unit preparations of the same or different specifications, used for simultaneous or separate administration of chlorogenic acid and temozolomide, as well as pharmaceutically acceptable carrier. 
     
     
         2 . The drug combination according to  claim 1 , characterized in that the mass ratio of chlorogenic acid and temozolomide is 35:100-350:100. 
     
     
         3 . The drug combination according to  claim 2 , characterized in that the mass ratio of chlorogenic acid and temozolomide is 85:100-200:100; the mass ratio of chlorogenic acid and temozolomide is 85:100-175:100; preferably, the mass ratio of chlorogenic acid and temozolomide is 100:100 or 200:100. 
     
     
         4 . The drug combination according to  claim 1 , characterized in that the preparation is an oral preparation or an injection preparation. 
     
     
         5 . The use of the drug combination according to  claim 1  in the preparation of drugs for treatment of high-grade brain tumors that recur after surgery and do not response to standard treatment. 
     
     
         6 . The use according to  claim 5 , characterized in that the brain tumors include glioblastoma, anaplastic astrocytoma, anaplastic oligodendrocytoma, and anaplastic oligodendroblastoma. 
     
     
         7 . A pharmaceutical composition, characterized in that it contains chlorogenic acid and temozolomide. 
     
     
         8 . The pharmaceutical composition according to  claim 7 , characterized in that the mass ratio of chlorogenic acid and temozolomide is 35:100-350:100. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , characterized in that the mass ratio of chlorogenic acid and temozolomide is 85:100-200:100; the mass ratio of chlorogenic acid and temozolomide is 85:100-175:100; preferably, the mass ratio of chlorogenic acid and temozolomide is 100:100 or 200:100. 
     
     
         10 . The method for preparation of the pharmaceutical composition according to  claim 7 , characterized in that it is a commonly used pharmaceutical preparation obtained by using chlorogenic acid and temozolomide as active ingredients, with addition of pharmaceutically acceptable excipients. 
     
     
         11 . The method according to  claim 10 , characterized in that the preparation is an oral preparation or an injection preparation. 
     
     
         12 . The use of the pharmaceutical composition according to  claim 7  in the preparation of drugs for treatment of high-grade brain tumors that recur after surgery and do not response to standard treatment. 
     
     
         13 . The use of chlorogenic acid in the preparation of drugs for treatment of high-grade brain tumors that recur after surgery and do not response to standard treatment. 
     
     
         14 . The use according to  claim 12 , characterized in that the brain tumors include glioblastoma, anaplastic astrocytoma, anaplastic oligodendrocytoma, and anaplastic oligodendroblastoma.